Key Drivers
- Strong cash flow
- High intangible load
- Elevated valuation
AIAI Summary
Revvity's pivot to high‑margin, recurring Signals software and AI partnerships creates meaningful long‑term upside, but the stock's current valuation is vulnerable to near‑term cyclicality (China DRG, academic R&D weakness) and large intangibles that could trigger impairments. Monitor Signals ARR growth/retention and management's capital‑allocation (buybacks vs reinvestment) over the next 4 quarters—accelerating ARR and disciplined reinvestment justify upgrading, while continued China weakness or impairment signs argue for holding or trimming.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash flow
- •High intangible load
- •Elevated valuation
RVTY generates strong cash flow, healthy liquidity and robust gross/EBITDA margins but trades at rich multiples with low ROA/ROE, heavy intangibles exceeding equity, and material leverage/SG&A risks.
Price Behavior
Key Price Behavior Insights:
- •Clear downtrend
- •Defined support
- •Resistance caps rallies
Over the last month RVTY has dropped ~14.3% from $100.33 to $85.95, finding near-term support at $84.70–$86 while rallies face resistance in the high-$90s–$100.33, signaling negative momentum with only a limited relief bounce and elevated volatility.
Multiple sharp drops from late-Feb highs into
Sentiment & News
Key News Insights:
- •Investor outreach
- •Signals software growth
- •China & research weakness
Revvity is actively engaging investors while showing strong diagnostics demand and rapid Signals software growth, but China policy pressures and weaker research spending are tempering near-term outlook.
Mixed fundamentals point to near-term stock volatility, though continued product momentum could drive medium-term upside if geopolitical and sectoral headwinds ease
Similar Companies in Healthcare
Other companies in the same sector with AI ratings